top of page

KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases. 

Our Company
City Skyline Across The Water

KLUS Pharma is based in Princeton, NJ and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China. 

Image by Tim Bogdanov

We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.

Image by Michael Longmire

We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials. 

About KLUS
Our Approach
mab%20picture_edited.jpg

Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.

bispecific antibodies 3.jpg

Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA. 

ADC.png

Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR. 

Apr 24, 2025

Kelun-Biotech will present the results from six clinical studies at the 2025 ASCO Annual Meeting including for innovative TROP2 ADC, anti-PD-L1 antibody, and novel RET fusion inhibitor.

Apr 21, 2025

Kelun-Biotech recently receives IND clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for its innovative ADC drug SKB518.

Mar 25, 2025

Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 receives IND approval from NMPA for clinical trials investigating the treatment of bone metastases in solid tumors.

Recent News

©2023 by KLUS Pharma Inc.

bottom of page